CMS Grants Permanent Product-specific Q-Code for Fresenius Kabi’s Stelara Biosimilar
The Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific billing code for Fresenius Kabi’s Otulfi (ustekinumab-aauz), an ustekinumab biosimilar referencing Stelara. Under the Healthcare Common Procedure Coding System (HCPCS), the Q-code Q9999 is for “Injection, for subcutaneous use or intravenous use, ustekinumab-aauz (Otulfi), biosimilar per 1.0mg.” Otulfi (ustekinumab-aauz) is U.S. Food and Drug (FDA)-approved […]